ImmunoCellular Therapeutics Ltd (AMEX:IMUC) - Overview

Stock Report

ImmunoCellular Therapeutics Ltd IMUC

Last Price
$2.66

Day Change
-0.02|-0.75%

As of 02/12/2016
15:59:11 EST | USD
Minimum 15 Minutes Delay.

Last Close2.68
Day Range2.55 - 2.89
Mkt Cap9.16Mil
52-Wk Range2.49 - 17.53
Yield %-
ISINUS4525362046
Volume97,974
P/E-0.31
P/S-
P/CF-0.30

Share Price

Financials
201320142015
More ...
Income Statement
Revenue0.000.00-
Operating Income-9.46-9.8615.51
Net Income-8.80-9.38-12.79
Basic EPS-6.40-6.40-6.00
Avg. Diluted Shares Outstanding112
Balance Sheet
Current Assets28.4124.4424.56
Non Current Assets0.530.745.52
Total Assets28.9425.1830.08
Current Liabilities1.401.292.27
Total Liabilities2.471.898.36
Total Equity26.4723.2921.72
Cash Flow
Operating Cash Flow-8.79-9.94-19.04
Capital Expenditure-0.04-0.03-0.17
Free Cash Flow-8.83-9.97-19.21

In millions, except "Basic EPS". Currency is USD.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Value

Fiscal Year Ends

December

Employees

-
Key Stats
More ...
Price/Earning TTM-0.32
Price/Book0.79
Price/Sales TTMInfinity
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % TTM-
Net Margin % TTM-
ROE TTM-56.83
Debt/Equity-
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.